Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: An in vivo assessment using dynamic MR imaging and macromolecular contrast media

Magnetic Resonance Imaging

Volumn 21, Issue 8, 2003, Pages 845-851

  Pradel, C ^a   Siauve, N ^a   Bruneteau, G ^a   Clement, O ^a   De Bazelaire, C ^a   Frouin, F ^b   Wedge, S R ^c   Tessier, J L ^c   Robert, P H ^a,d   Frija, G ^a   Cuenod, C A ^a  

^a Institut Necker   (France)

^b INSERM   (France)

^c ASTRAZENECA   (United Kingdom)

^d Laboratoire Guerbet   (France)

Author keywords

Hemodynamic; ppMRI; VEGF; ZD4190

Indexed keywords

CONTRAST MEDIUM; GADOMELITOL; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PERFUSION; CAPILLARY PERMEABILITY; CONTROLLED STUDY; HEMODYNAMICS; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 10744232021     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(03)00186-3     Document Type: Article

References (38)

1. Folkman J. Tumour angiogenesis. Adv Cancer Res 1985;43:175-203.
2. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC) 1989;246:1309-12.
3. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
4. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important regulator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233-5.
5. Gerlowski LE, Jain R. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
6. Ortéga N, Jonca F, Vincent S, Favard C, Ruchoux M-M, Plouët J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol 1997;151:1215-24.
7. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273:31273-82.
8. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha H-J, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J 1999;18:363-74.
9. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad spectrum antitumor efficacy. Cancer Res 2000;60:970-5.
10. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57:4777-86.
11. Furman-Haran E, Grobgeld D, Degani H. Dynamic contrast-enhanced imaging and analysis at high spatial resolution of MCF-7 human breast tumours. J Magn Reson 1997;128:161-71.
12. Eskey CJ, Koretsky AP, Domach MM, Jain RK. 2H-Nuclear magnetic resonance imaging of tumour blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 1992;52:6010-19.
13. Zhu XP, Li KL, Kamaly-Asi MB, Checkley DR, Tessier JJL, Waterton JC, Jackson A. Quantification of endothelial permeability, leakage space and blood volume in brain tumours using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575-85.
14. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 1991;17:357-67.
15. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-8.
16. Larsson HBW, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-31.
17. Li KL, Zhu XP, Waterton JC, Checkley D, Tessier JJL, Watson Y, Jackson A. Improving estimates of endothelial permeability surface area product using constrained fitting parameters for the estimation of the plasma tracer concentration function (PTCF), Proceedings of the 8th International Society for Magnetic Resonance in Medicine 2000, Abstract 1968.
18. Pham CD, Roberts TP, van Bruggen N, Melnik O, Mann J, Ferrara N, Cohen RL, Brasch RC. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-30.
19. Clement O, Pradel C, Siauve N, Frouin F, Bruneteau G, Kahn E, Frija G, Cuenod CA. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Acad Radiol 2002;9(Suppl. 2):S328-9 [Abstract].
20. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
21. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee J, Dencausse A, Le Greneur S, Simonot C, Meyer D. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. MAGMA 2001;12:121-7.
22. Port M, Corot C, Raynal I, Idee J, Dencausse A, Lancelot E, Meyer D, Bonnemain B, Lautrou J. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Invest Radiol 2001;36:445-54.
23. Berman M, Weiss MF. SAAM manual. US Department of Heath, Education and Welfare Publication No. (NIH)78-180. Bethesda, MD: National Institutes of Health, 1978.
24. Berman M, Beltz WF, Greif PC, Chabay R, Boston RC. CONSAM user's guide. US Dept of Health and Human Services: Public Health Service. Bethesda, MD: National Institutes of Health, 1983.
25. de Bazelaire C, Siauve N, Fournier L, Frouin F, Vernoux S, Kahn E, Clement O, Frija G, Cuenod CA. Comprehensive model for simultaneous perfusion and permeability MRI. Magn Reson Med (Submitted Aug. 02).
26. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee TY, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Res Imaging 1999;10:223-32.
27. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + Paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proceedings of the American Society of Clinical Oncology 2001. Abstract 1256.
28. Jayson GC, Mulatero C, Ranson M, Zweit J, Hastings D, Julyan P, Lawrance J, McGown A, Jackson A, Haroon H, Hakannson L, Wagstaff J, Groenewegen G, Lehmann F, Levitt D, Tang T, Zweirzina H. Anti-VEGF antibody HuMV833: an EORTC Biological Treatment Development Group phase I toxicity, pharmacokinetic and pharmacodynamic study. Proceedings of the American Society of Clinical Oncology 2001. Abstract 14.
29. Basser R, Hurwitz H, Barge A, Davis I, DeBoer R, Holden S, McArthur G, McKinley M, Nairn K, Persky M, Rischin D, Rosenthal M, Swaisland H, Eckhardt G. Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proceedings of the American Society of Clinical Oncology 2001. Abstract 396.
30. Checkley D, Tessier JLT, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 2002 (In press).
31. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
32. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-30.
33. van Dijke C, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames DM, Mann JS, Demsar F, Lang P, Schwickert HC. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-18.
34. Schwickert HC, Stiskal M, Roberts TP, van Dijke CF, Mann J, Muhler A, Shames DM, Demsar F, Disston A, Brasch RC. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996;198:893-8.
35. Shames DM, Kuwatsumi R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993;29:616-22.
36. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-8.
37. 1H NMR studies of rat brain tumor pH and blood flow during acute hyperglycemia: differential effects between subcutaneous and intracerebral locations. Magn Reson Med 1989;12:219-34.
38. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-9.